Tag: mesenchymal stem cells

December 10, 2018

Genetics Outlook 2019: CRISPR Technology Advances

With 2018 coming to a close, here's a look at the biggest genetics trends of the year and what's in...
August 23, 2018

BrainStorm Cell Therapeutics Announces Positive Interim Safety Analysis

On Thursday, BrainStorm Cell Therapeutics announced that its Phase 3 trial for NurOwn in patients with ALS will be able...
April 20, 2018

Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a...
March 29, 2018

Cynata Therapeutics Receives Orphan Drug Designation from FDA

The orphan drug designation is a unique mission that incentivizes companies to develop treatments for the rare disease market.
February 17, 2017

Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn's Disease Patients with Cx601

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG)  (“TiGenix”) today announced new data...
February 9, 2017

What Are Mesenchymal Stem Cells?

What exactly are mesenchymal stem cells … and more importantly, why should investors care?
February 8, 2017

BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease

BioRestorative Therapies, Inc. (“BRT” or the “Company”) (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that...